Division of Hematology-Oncology, Department of Medicine, University of Michigan School of Medicine, Ann Arbor, Michigan, USA.
Cancer Res. 2013 Jan 15;73(2):930-41. doi: 10.1158/0008-5472.CAN-12-1389. Epub 2012 Nov 16.
Activating NOTCH1 mutations are found in 50% to 60% of human T-cell acute lymphoblastic leukemia (T-ALL) samples. In mouse models, these mutations generally fail to induce leukemia. This observation suggests that NOTCH1 activation must collaborate with other genetic events. Mutagenesis screens previously implicated ZMIZ1 as a possible NOTCH1 collaborator in leukemia. ZMIZ1 is a transcriptional coactivator of the protein inhibitor of activated STAT (PIAS)-like family. Its role in oncogenesis is unknown. Here, we show that activated NOTCH1 and ZMIZ1 collaborate to induce T-ALL in mice. ZMIZ1 and activated NOTCH1 are coexpressed in a subset of human T-ALL patients and cell lines. ZMIZ1 inhibition slowed growth and sensitized leukemic cells to corticosteroids and NOTCH inhibitors. Gene expression profiling identified C-MYC, but not other NOTCH-regulated genes, as an essential downstream target of ZMIZ1. ZMIZ1 functionally interacts with NOTCH1 to promote C-MYC transcription and activity. The mechanism does not involve the NOTCH pathway and appears to be indirect and mediated independently of canonical PIAS functions through a novel N-terminal domain. Our study shows the importance of identifying genetic collaborations between parallel leukemic pathways that may be therapeutically targeted. They also raise new inquiries into potential NOTCH-ZMIZ1 collaboration in a variety of C-MYC-driven cancers.
NOTCH1 激活突变存在于 50%至 60%的人类 T 细胞急性淋巴细胞白血病 (T-ALL) 样本中。在小鼠模型中,这些突变通常不能诱导白血病。这一观察结果表明,NOTCH1 的激活必须与其他遗传事件协同作用。先前的诱变筛选将 ZMIZ1 鉴定为白血病中 NOTCH1 的可能协同因子。ZMIZ1 是激活 STAT 蛋白抑制剂 (PIAS)-样家族的转录共激活因子。其在肿瘤发生中的作用尚不清楚。在这里,我们表明激活的 NOTCH1 和 ZMIZ1 协同诱导小鼠发生 T-ALL。ZMIZ1 和激活的 NOTCH1 在一部分人类 T-ALL 患者和细胞系中共同表达。ZMIZ1 抑制减缓了生长速度,并使白血病细胞对皮质类固醇和 NOTCH 抑制剂敏感。基因表达谱分析确定 C-MYC 是 ZMIZ1 的一个必需下游靶点,但不是其他 NOTCH 调节的基因。ZMIZ1 与 NOTCH1 功能相互作用,促进 C-MYC 转录和活性。该机制不涉及 NOTCH 途径,并且似乎是间接的,通过 novel N-terminal 结构域独立于经典的 PIAS 功能介导。我们的研究表明,确定可能成为治疗靶点的平行白血病途径之间的遗传协同作用非常重要。它们还引发了对各种 C-MYC 驱动的癌症中潜在的 NOTCH-ZMIZ1 协同作用的新探究。